Latest News From Pharmachem
-
Irish-headquartered clinical trials firm Icon to create 200 jobs
01 February, 2015
Irish-headquartered clinical trials firm Icon to create 200 jobs
-
Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award
03 February, 2015
Four initiatives from across Africa win share of global US$1 million Healthcare Innovation Award
-
ICON to buy US-based MediMedia Pharma Solutions
03 February, 2015
Irish multinational company ICON has announced a deal to buy US-based MediMedia Pharma Solutions for $120m.
-
Guinea approves Fujifilm's Avigan to treat early Ebola cases
09 February, 2015
INGAPORE--The head of Guinea's Ebola-response program wasted no time announcing approval of Fujifilm's Avigan (favipiravir) influenza drug to treat early cases of Ebola in the West African nation.Program Coordinator Sakoba Keita said the drug, developed by Fujifilm's Toyama Chemical unit, would be available only in three special Ebola-treatment centers in the country and possibly two additional centers later. Using Avigan to treat patients with low to moderate levels of the virus in their blood will be limited to those clinics. The drug would not be made available to patients in hospitals, either public or private, the government said. "It takes training of health workers on the use of this drug," the announcement said. The government acted soon after Toyama disclosed preliminary results from Phase I clinical trials showing the drug trimmed the mortality rate in early stages to 15% from 30%. The patients also reported no adverse side effects from Avigan.
-
Voxpro tie-up with US skincare group creates 43 jobs in Cork
10 February, 2015
Irish multilingual call centre partners with It Works!
-
Government to announce regional strategy on jobs today
11 February, 2015
The Government is announcing its regional strategy under the Action Plan for Jobs this morning.
-
Cost of Soliris drug will impact other areas of health service, says HSE chief
12 February, 2015
The head of the HSE has admitted that the rest of the health service will have to suffer because of a decision to pay for expensive drugs for patients with a rare blood disorder.
-
GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG
13 February, 2015
GSK has acquired GlycoVaxyn AG, a specialist vaccine biopharmaceutical company based in Switzerland. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn and has now acquired the remaining shares for US $190 million (approximately £124 million) in cash to take full ownership of the company.
-
Short-term use of hormone replacement therapy associated with increased ovarian cancer risk
16 February, 2015
Taking hormone replacement therapy (HRT) for the menopause, even for just a few years, is associated with a significantly increased risk of developing the two most common types of ovarian cancer, according to a detailed re-analysis of all the available evidence, published in The Lancet.
-
New therapeutic principle for Parkinsonian dyskinesia shows clinical effect
17 February, 2015
Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson's disease. Now, however, researchers at Karolinska Institutet and Lund University in Sweden seem to be close to a novel therapy to this distressing side effect.
-
Sanofi and Lead Pharma to develop treatments for autoimmune diseases
19 February, 2015
Sanofi announced today that it has entered into a research collaboration and license agreement with Dutch biotech Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease, which are among the most common.
-
New test to predict the effectiveness of cancer vaccines
20 February, 2015
Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells.
-
iManageCancer Survey: Your Opinion Counts
23 February, 2015
Would you like to contribute to the future of cancer treatment in technology? iManageCancer project is trying to find out how mobile healthcare (mHealth) and serious games might help people with chronic illnesses and in particular cancer. Significant improvements due to cancer research have led to more cancer patients being cured, and very many more enabled to live with their condition.
-
Horizon Pharma opens new global headquarters in Dublin
24 February, 2015
Company to create 60 highly-skilled jobs in Dublin over next three years
-
Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
25 February, 2015
Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak® (panobinostat, previously known as LBH589) capsules in combination with bortezomib* and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory (IMiD) agent[1]
-
Graphene shows potential as novel anti-cancer therapeutic strategy
26 February, 2015
University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells. This new development opens up the possibility of preventing or treating a broad range of cancers, using a non-toxic material. Writing in the journal Oncotarget, the team of researchers led by Professor Michael Lisanti and Dr Aravind Vijayaraghavan has shown that graphene oxide, a modified form of graphene, acts as an anti-cancer agent that selectively targets cancer stem cells (CSCs).
-
Omega-3 fatty acids and vitamin D may control brain serotonin
27 February, 2015
Although essential marine omega-3 fatty acids and vitamin D have been shown to improve cognitive function and behavior in the context of certain brain disorders, the underlying mechanism has been unclear. In a new paper published in FASEB Journal by Rhonda Patrick, PhD and Bruce Ames, PhD of Children's Hospital Oakland Research Institute (CHORI), serotonin is explained as the possible missing link tying together why vitamin D and marine omega-3 fatty acids might ameliorate the symptoms associated with a broad array of brain disorders.